3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Prostatic Neoplasms
25
Breast Neoplasms
22
Salivary Gland Neoplasms
3
Prostate Adenocarcinoma
2
Neoplasm Metastasis
2
Breast Neoplasms, Male
2
Triple Negative Breast Neoplasms
1
Stage I Prostate Adenocarcinoma AJCC v7
1
Sexual Dysfunctions, Psychological
1
Primary Dysautonomias
1
Patient Compliance
1
PSA Level Greater Than Two
1
Kidney Diseases
1
Hypertension
1
Hormone Sensitive Prostate Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
HER2-positive Breast Cancer
1
HER2 Negative Breast Cancer
1
Castrate Sensitive Prostate Cancer
1
Bulbo-Spinal Atrophy, X-Linked
1
Anatomic Stage I Breast Cancer AJCC v8
1
Advanced Breast Cancer
1
Interventions
Fulvestrant
5
serabelisib
2
sapanisertib
2
ribociclib
2
palbociclib
2
Paclitaxel
2
Letrozole
2
Irinotecan
2
Gemcitabine
2
Carboplatin
2
Alpelisib
2
venetoclax
1
tivozanib
1
tipifarnib
1
sotorasib
1
pembrolizumab
1
olaparib
1
niraparib
1
lorlatinib
1
liposomal doxorubicin
1
inavolisib
1
exemestane
1
encorafenib
1
ceralasertib
1
cemiplimab
1
capivasertib
1
binimetinib
1
abemaciclib
1
Taxes
1
Tamoxifen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
Goserelin
×
1 year
×
Clear all
NCT03056755
2026-01-13
BYLieve
Novartis
Phase 2
Completed
383 enrolled
16 charts